KOD – Technical Market Research
KOD surged 75% on GLOW2 Phase 3 success for tarcocimab (Zenkuda). RSI at 89 — deep overbought. The setup now is about defining where the mean-reversion risk is real vs. where momentum continues.
Published March 27, 2026 | Equity | KOD
Rachel Kensington
Senior Equity Analyst · Blue Ocean Trading Solutions
Technical Overview
The tape is screaming. Kodiak Sciences printed a 75% single-session gap yesterday on massive volume — 13.2 million shares traded against an average daily volume of just 744,000. That's an 18x volume surge. When you see that kind of dislocating move on that kind of liquidity, you don’t just shrug and move on. You ask: what’s driving the structure from here?
